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A 66-year-old male patient was referred to our hospital for bilateral renal pelvic tumors. Ureteroscopic
biopsy revealed urothelial carcinoma (UC) of low grade (G1) of the renal pelvis. Renal sparing treatment
with systemic chemotherapy and percutaneous tumor resection was performed. However, during
subsequent follow up, a recurrent tumor was found on the left ureter. After ureteroscopic laser ablation of
the tumor, Bacillus Calmette-Guerin (BCG) perfusion therapy (once a week, total 6 weeks) was performed via
a single J ureteral catheter with no adverse events. Later, another recurrent recurrence was found on the
right ureter, and was managed by ureteroscopic laser ablation followed by BCG perfusion therapy via a single
J ureteral catheter. However, the patient developed high fever with chill from the day after initial BCG
perfusion therapy on the right side. Although we started antibiotics, high fever continued. Then anti-
tuberculous drugs were administered and his condition was improved. Computed tomographic scan
revealed a right renal mass 57 mm in diameter, which was consistent with tuberculous granuloma. The
tuberculous granuloma persisted despite the continuation of anti-tuberculous drugs. In exceptional cases of
upper tract UC such as single kidney and bilateral tumor, BCG perfusion therapy has been used as adjunctive
treatment to cure or prevent UC. However, dosages and administration methods of BCG perfusion therapy
for upper tract UC still remain to be standardized. Serious adverse events after BCG perfusion therapy
require prompt and proper management including the use of anti-tuberculous drugs.
(Hinyokika Kiyo 62 : 25-28, 2016)














患 者 : 66歳，男性
既往歴および家族歴 : 特記事項なし
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Fig. 1. Abdominal enhanced CT scan showing renal
pelvic tumors on both sides.
泌61,01,0◆-2
Fig. 2. Abdominal enhanced CT scan showing a 57
mm mass in the right kidney.
腫瘍縮小およびその後の腎温存手術の可能性を考慮
し，化学療法としてゲムシタビンとシスプラチンを組






瘍の volume は多いものの，生検結果からは low
grade，low stage の腫瘍である可能性を考慮し， 2期
的に両側経皮的腎盂腫瘍切除術を施行した．病理所見
は両側ともに UC，low grade，pTa であった．再発予
防目的に両側とも腎瘻経由で MMC 40 mg を生理食塩






laser ablation を施行した． 8月から再発予防目的に左
尿管ステント（Single J，7 Fr）留置下に BCG を初回





た．左同様に尿管鏡下に laser ablation にて腫瘍を切除
した後，右尿管ステント（Single J）留置下 BCG 腎盂
内注入を行った．
透視下に右尿管に single J カテーテル（8 Fr）を挿
入し，左側と同様に Gianluca10) らの報告に準じて





流療法による播種性 BCG 感染症として，投与後 3日
目から抗結核薬のイソニアジド 300 mg＋リファンピ
シン 450 mg＋エタンブトール 375 mg の 3剤併用療法
を開始した．その後一旦解熱したが，投与後14日目で
再び発熱を認めた．CTにて右腎に 57×35 mm の腫瘤
性病変認めた（Fig. 2）．その後抗結核薬を増量したも
のの発熱が継続したことから，投与16日目でレボフロ
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Sharpe, et al.1) 17 Ureteral catheter 1 hour 360/150 Fever (1), Hematuria (3)
Yokogi, et al.2) 8
Ureteral catheter (3),
Nephrostomy (5) 2 hour 80/80
Renal tuberculosis (1, 0), Ureteric
stricture (1, 0)
Nishino, et al.3) 6 Ureteral catheter (3), JJ stent (3) 2 hour 80/100 Fever (1, 3)
Nonomura, et al.4) 11 JJ stent ― 80/40 Fever (4)
Okubo, et al.5) 14
Ureteral catheter (12),
Nephrostomy (2) 1 hour 40/50 Ureteric stricture (2, 0)
Irie, et al.6) 9 JJ stent ―
1-2 mg/ml
(80-200 ml) Fever (2), Hematuria (2), Arthritis (1)
Miyake, et al.7) 16
Ureteral catheter (2), JJ stent
(9), Nephrostomy (5) 2 hour 80/80 Fever (9)
Hayashida, et al.8) 11
Ureteral catheter (2), JJ stent
(4), Nephrostomy (4) 1 hour
0.8-1.6
mg/ml Fever (9), Hematuria (2)
Kojima, et al.9) 17
Ureteral catheter (1), JJ stent
(16) 1 hour 80/40
Fever (3), Hematuria (3), Creatinine
elevate (1)
Giannarini, et al.10) 64 Nephrostomy (64) 2 hour
360/150 or
243/150
Fever (5), Pericarditis (1), Hematuria (1),
Infection (2), Septicaemia (2)
Table 2. Statistical analysis of the prevalence of side
effects according to perfusion methods,
administration time and dose of BCG
Method No of renal units Side effect n (％) P (t-test)
Retrograde 72 28 (39) ―
Antegrade 71 11 (15) 0.002
Administration
time No of renal units Side effect n (
％) P (t-test)
1 hour 59 24 (41) ―
2 hour 94 26 (28) 0.095
Dose (BCG
mg/saline ml) No of renal units Side effect n (
％) P (t-test)
1 (mg/ml) ≧ 44 17 (39) ―









報告を Table 1 にまとめた．投与経路としては，腎瘻
経由の順行性の薬剤投与，single J カテーテル経由の




が Table 2 である．腎瘻経由の順行性投与に比べて，






















































Single J 尿管カテーテル挿入下での BCG 腎盂内灌
流療法により，結核性肉芽腫と思われる腫瘤を形成し
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